Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
ADNOC Gas Targets Up to $4B Profit in 2026 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and Drug Administration’s (FDA) new national priority voucher, positioning it for potentially accelerated approval. The pharmaceutical giant plans to submit its application this quarter, with the FDA set to determine the review timeline. Under the new program, qualifying drugs can receive review periods as short as one to two months, compared to the usual ten to twelve.
The criteria for the voucher program include innovation, addressing unmet medical needs, and supporting U.S. manufacturing—three areas in which Lilly claims strong alignment. The GLP-1 pill demonstrated significant effectiveness in late-stage trials, helping patients lose 12.4% of body weight, and Lilly has invested heavily in domestic production facilities to meet future demand.
The FDA recently announced the first nine recipients of this voucher, including Merck KGaA, Sanofi, and Regeneron, signaling heightened competition in the accelerated drug review space.
Alongside regulatory progress, Lilly reported a major earnings beat, driven by surging international demand for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound. Third-quarter earnings reached $7.02 per share, well above analyst expectations of $5.69. Sales of Mounjaro totaled $6.5 billion, while Zepbound brought in $3.6 billion, both surpassing projections.
Lilly raised its full-year profit outlook to between $23.00 and $23.70 per share, up from previous guidance. The company now expects annual revenue between $63 billion and $63.5 billion. Analysts credit strong overseas demand and consistent consumer interest in weight-loss therapies for Lilly’s sustained growth, solidifying its leadership position against rival Novo Nordisk. As the global market for obesity drugs accelerates toward an estimated $150 billion by decade’s end, Eli Lilly continues to dominate the sector with robust innovation and expanding market share.
